NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 65 resultados LastUpdate Última actualización 21/07/2017 [14:17:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES

NºPublicación: EP3192809A1 19/07/2017

Solicitante:
LILLY CO ELI [US]

Resumen de: EP3192809A1

Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).



traducir


 

5'-POSITION DIBENZYL PHOSPHORIC ACID ESTER OF 5-AZACYTIDINE OR 2'-DEOXY BODY THEREOF

NºPublicación: EP3192799A1 19/07/2017

Solicitante:
OHARA PHARMACEUTICAL CO LTD [JP]

Resumen de: EP3192799A1

The present invention relates to a novel compound represented by formula (1), or salt thereof, wherein R is hydroxy group or hydrogen atom; R 1 and R 2 are the same or different, and are each independently benzyl group which may have a substituent. The present invention provides therapeutically agents, which have remarkable stability against cytidine deaminase, a metabolic enzyme, can be absorbed in vivo by oral administration and inhibit protein synthesis by being incorporated easily into nucleic acid bio-synthesis in vivo for replacing injection agent (5-azacytidine or 2'-deoxy-5-azacytidine) used in clinic for treating myeloma.



traducir


 

COBALT PORPHYRINS FOR THE TREATMENT OF BLOOD-RELATED DISORDERS

NºPublicación: US2017196882A1 13/07/2017

Solicitante:
UNIV JAGIELLONSKI [PL]

Resumen de: US2017196882A1

The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem cells in peripheral blood for subsequent isolation in the process of apheresis and allogeneic or autologous transplantation.



traducir


 

DISEASE MODELS AND PROGNOSTIC TOOLS FOR PRE-LEUKEMIA AND LEUKEMIA

NºPublicación: WO2017117685A1 13/07/2017

Solicitante:
UNIV MCMASTER [CA]

Resumen de: WO2017117685A1

The present disclosure describes methods for creating a disease model of myelodysplastic syndrome and acute myeloid leukemia syndrome by creating gene knockouts of GSK-3β or double knockouts of GSK-3α and GSK-3β, respectively. Also described are uses of these models for classifying human myeloid pre-neoplastic and neoplastic subtypes in reference to a GSK-3β gene signature and determining risk stratification of a subject with myelodysplastic syndrome and prognosis based on their gene expression profile. The models and the GSK-3β signature are useful for guiding treatment decisions or for monitoring treatment response. The disease models and the cells derived from them as described herein are also useful for screening and evaluating the effectiveness of test agents for treatment of MDS or leukemia.



traducir


 

USE OF ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE ANTIBODY FOR THE TREATMENT OF B-CELL MALIGNANCIES SYMPTOMS

NºPublicación: US2017196988A1 13/07/2017

Solicitante:
SANOFI SA [FR]

Resumen de: US2017196988A1

An anti-CD19 maytansinoid immunoconjugate is used for treating B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma.



traducir


 

INHIBITION OF P38 MAPK FOR THE TREATMENT OF CANCER

NºPublicación: WO2017117182A1 06/07/2017

Solicitante:
BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]

Resumen de: WO2017117182A1

Methods are provided for treating cancer patients who have elevated expression of FOXC2. In certain aspects, patients having elevated FOXC2 are treated with an anti-cancer therapy in conjunction with a p38 MAPK inhibitor. Methods of identifying cancer patients to be treated with p38 MAPK inhibitors are also provided. Further provided herein are methods for treating and/or preventing breast cancer metastasis by the administration of a p38 MAPK inhibitor. In certain aspects, patients are treated with an anti-cancer therapy in conjunction with a p38 MAPK inhibitor. In addition, methods are provided for the treatment of BCR-ABL positive cancers, such as acute lymphoblastic leukemia, by the administration of a p38 MAPK inhibitor and/or a glucocorticoid inhibitor in combination with a tyrosine kinase inhibitor.



traducir


 

PML GENE AND RARA GENE DETECTION PROBE, PREPARATION METHOD THEREFOR, AND TEST KIT

NºPublicación: WO2017114007A1 06/07/2017

Solicitante:
GUANGZHOU LBP MEDICINE SCIENCE AND TECH CO LTD [CN]

Resumen de: WO2017114007A1

Provided are a PML gene and RARA gene detection probe, and a preparation method therefor, the method comprising the following steps: selecting a BAC clone for the PML gene to be at least one of RP11-832J18, CTD-2529B11, RP11-756N20 and RP11-1031J4, and selecting a BAC clone for the RARA gene to be at least one of CTD-2360L10, RP11-737D6, CTD-3087O22, RP11-48O10 and CTD-2134K5; obtaining plasmid DNA; labelling. Also provided is a test kit which includes the PML gene and RARA gene detection probe and detects the acute promyelocytic leukaemia PML and RARA fusion gene.



traducir


 

MIRNA ASSAY METHOD FOR DISTINGUISHING BETWEEN REACTIVE LYMPHOID HYPERPLASIA AND LYMPHOMA

NºPublicación: WO2017113972A1 06/07/2017

Solicitante:
CHENGDU NUOEN BIOLOG TECH CO LTD [CN]

Resumen de: WO2017113972A1

The present invention provides a miRNA assay method for distinguishing between reactive lymphoid hyperplasia and lymphoma. The assay method comprises a quantitative test of a related miRNA in a fine-needle aspiration sample, a biopsy sample, or a formalin-fixed paraffin-embedded sample. The quantity of miRNA detected by the test is then classified and undergoes a comparative analysis to predict whether the sample is caused by reactive lymphoid hyperplasia or lymphoma.



traducir


 

KIT FOR DETECTING FUSION GENES ASSOCIATED WITH ACUTE PROMYELOCYTIC LEUKEMIA

NºPublicación: WO2017113148A1 06/07/2017

Solicitante:
ANNOROAD GENE TECH (BEIJING) CO LTD [CN]

Resumen de: WO2017113148A1

Provided is a kit for detecting fusion genes associated with acute promyelocytic leukemia (APL). Specifically, provided are a detection kit and a gene detection method capable of simultaneously detecting a plurality of RARα fusion genes associated with APL on the basis of the second-generation sequencing technology, and a method for constructing a second-generation sequencing DNA library and a library construction kit for use in the detection method.



traducir


 

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF

NºPublicación: WO2017117406A1 06/07/2017

Solicitante:
KARYOPHARM THERAPEUTICS INC [US]

Resumen de: WO2017117406A1

The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (I) or (II), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.



traducir


 

MULTICYCLIC COMPOUNDS AND USES THEREOF

NºPublicación: WO2017117447A1 06/07/2017

Solicitante:
KARYOPHARM THERAPEUTICS INC [US]

Resumen de: WO2017117447A1

The present invention relates to multicyclic compounds containing a urea or a guanidine moiety, or pharmaceutically acceptable salts or compositions thereof represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof and pharmaceutical comopositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disesase) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.



traducir


 

ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING MULTIPLE MYELOMA

NºPublicación: US2017190784A1 06/07/2017

Solicitante:
ACCELERON PHARMA INC [US]

Resumen de: US2017190784A1

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.



traducir


 

Lobaplatin Crystal, Preparation Method And Pharmaceutical Application

NºPublicación: US2017189367A1 06/07/2017

Solicitante:
GUIZHOU YIBAI PHARMACEUTICAL COMPANY LTD [CN]

Resumen de: US2017189367A1

The present invention relates to new crystals A, B and F of lobaplatin as well as preparation methods therefor and pharmaceutical applications thereof. Lobaplatin crystal A has a melting point Tm.p. of 220±5° C. and is obtained by adding a lobaplatin trihydrate to a suspension crystallization solvent. Lobaplatin crystal B has a melting point Tm.p. of 230±5° C. and is obtained by performing solvent evaporation on a lobaplatin trihydrate or by adding a solvent to a lobaplatin dihydrate, and performing room temperature evaporation or solventing-out crystallization and then drying. Lobaplatin crystal F has a melting point Tm.p. of 229±5° C. and is obtained by adding methanol or ethanol to a lobaplatin dihydrate, stirring at room temperature until solids are dissolved, filtering out insolubles, slowly adding an organic solvent, crystallizing out, separating the crystal and drying the crystal. Compared with the existing lobaplatin and lobaplatin trihydrate, the lobaplatin crystals A, B and F have better stability and solubility, are more suitable for preparation of various forms of pharmaceutical preparations, are more suitable for storage and use, and can be better used for treating cancers such as breast cancer, small cell lung cancer, or chronic myeloid leukemia.



traducir


 

BUTYROYLOXYMETHYL DIETHYL PHOSPHATE COMPOUNDS AND USES THEREOF

NºPublicación: US2017189376A1 06/07/2017

Solicitante:
MOR RES APPLICATIONS LTD [IL]
BAR-ILAN UNIV [IL]

Resumen de: US2017189376A1

Methods for treating ameliorating, reducing and/or preventing a cutaneous T-cell lymphoma in a subject in need thereof, comprising administration butyroyloxymethyl diethyl phosphate (AN-7) alone or combined with an additional anti-cancer therapy.



traducir


 

COMPOUNDS FOR TREATING BRAIN CANCER

NºPublicación: US2017189382A1 06/07/2017

Solicitante:
PURDUE PHARMACEUTICAL PRODUCTS L P [US]
PURDUE PHAMACEUTICAL PRODUCTS L P [US]

Resumen de: US2017189382A1

for use in the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumor, a metastatic brain cancer and primary CNS lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula I or a pharmacologically acceptable salt thereof.



traducir


 

Methods for Manipulating Phagocytosis Mediated by CD47

NºPublicación: US2017190776A1 06/07/2017

Solicitante:
UNIV LELAND STANFORD JUNIOR [US]

Resumen de: US2017190776A1

Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.



traducir


 

Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same

NºPublicación: US2017190700A1 06/07/2017

Solicitante:
BAKARE OLADAPO [US]
DENMEADE SAMUEL RAY [US]
AKINBOYE EMMANUEL S [US]

Resumen de: US2017190700A1

Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the N2′-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment. Such compounds are less cytotoxic than emetine and are substantially inactive in non-cancerous cells. In one aspect, the compounds described herein can be used for the treatment of metastatic and non-metastatic cancers, including, for example, breast cancer, prostate cancer, lung cancer, and leukemia.



traducir


 

METHODS OF TREATING ACUTE MYELOID LEUKEMIA OR ACUTE LYMPHOID LEUKEMIA USING PHARMACEUTICAL COMPOSITIONS CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS

NºPublicación: EP3185871A1 05/07/2017

Solicitante:
ONCOETHIX GMBH [CH]

Resumen de: WO2016030509A1

A method of treating acute myeloid leukemia or acute lymphoid leukemia in a mammal comprising the step of: administering a pharmaceutically acceptable amount of a thienotriazolodiazepine compound represented by the following Formula (1): wherein R1 is alkyl having a carbon number of 1-4, R2 is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R3 is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1 - 4, alkoxy having a carbon number of 1-4 or cyano;— NR5—(CH2)m—R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R6 is phenyl or pyridyl optionally substituted by a halogen atom; or -NR7—CO—(CH2)n—R8 wherein R7 is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R8 is phenyl or pyridyl optionally substituted by a halogen atom, and R4 is—(CH2)a—CO—NH—R9 wherein a is an integer of 1-4, and R9 is alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or—(CH2)b—COOR10 wherein b is an integer of 1-4, and R10 is alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof.



traducir


 

Methods for treating cancer using tor kinase inhibitor combination therapy

NºPublicación: NZ629456A 30/06/2017

Solicitante:
SIGNAL PHARM LLC

Resumen de: NZ629456A

Disclosed herein is the use of an effective amount of an effective amount of a TOR kinase inhibitor represented by structural formula (I) and an effective amount of IMiD immunomodulatory drug in the manufacture of a medicament for treating or preventing cancer, particularly blood borne cancer which includes a lymphoma, a leukemia or a mutliple myeloma, wherein the variables shown in formula (I) are as defined in the specification.



traducir


 

Treatment of cancer with dihydropyrazino-pyrazines

NºPublicación: NZ629411A 30/06/2017

Solicitante:
SIGNAL PHARM LLC

Resumen de: NZ629411A

Disclosed herein is the use of an effective amount of a dihydropyrazino-pyrazine represented by structural formula (I) in the manufacture of a medicament for treating or preventing chronic lymphocytic leukemia (CLL), or T-cell prolymphocytic leukemia (T-PLL) characterized by one or more of deletion of all or part of chromosome 11q, loss or mutation of the gene encoding ATM, loss of ATM expression or function, mutation of IgVH, wild type IgVH, wild type p53/ATM, mutation of p53, dysfunctional p53 or Zap-70 positivity, or T-PLL. The preferred dihydropyrazino-pyrazine is 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer or isotopologue thereof.



traducir


 

Methods for treating cancer using tor kinase inhibitor combination therapy

NºPublicación: NZ631082A 30/06/2017

Solicitante:
SIGNAL PHARM LLC

Resumen de: NZ631082A

Disclosed herein is the use of an effective amount of an effective amount of a TOR kinase inhibitor represented by structural formula (I) and an effective amount of a cytidine analog in the manufacture of a medicament for treating or preventing cancer, particularly blood borne cancer which includes a lymphoma, a leukemia or a mutliple myeloma, wherein the variables shown in formula (I) are as defined in the specification.



traducir


 

BISPECIFIC ANTI-CD20/ANTI-CD3 ANTIBODIES TO TREAT ACUTE LYMPHOBLASTIC LEUKEMIA

NºPublicación: WO2017112762A1 29/06/2017

Solicitante:
REGENERON PHARMA [US]

Resumen de: WO2017112762A1

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of acute lymphoblastic leukemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.



traducir


 

COMBINATION OF ANTI-PD-1 ANTIBODIES AND BISPECIFIC ANTI-CD20/ANTI-CD3 ANTIBODIES TO TREAT CANCER

NºPublicación: WO2017112775A1 29/06/2017

Solicitante:
REGENERON PHARMA [US]

Resumen de: WO2017112775A1

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., a B-cell cancer such as Hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.



traducir


 

PHARMACEUTICAL COMPOSITION COMPRISING AMORPHOUS DASATINIB

NºPublicación: WO2017108605A1 29/06/2017

Solicitante:
SYNTHON BV [NL]

Resumen de: WO2017108605A1

The present invention relates to a tablet composition comprising a solid dispersion of dasatinib and a polymer, wherein the composition is obtained by: (1) Dissolving dasatinib and the polymer in a solvent mixture comprising water, an alcohol and at least one molar equivalent of acid with respect to dasatinib at a temperature ranging from 45 to 70ºC; (2) Adding the resulting solution to a diluent; (3) Evaporating the solvent; (4) Mixing the resulting blend with further excipients; (5) Compressing the final blend into tablets, what wherein the polymer is selected from polyvinylpyrrolidone, copovidone and hydroxypropyl cellulose. The invention further relates to the use of said tablet composition as a medicament, particularly in the treatment of chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL).



traducir


 

BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPY

Nº publicación: WO2017112703A1 29/06/2017

Solicitante:
CELGENE QUANTICEL RES INC [US]

Resumen de: WO2017112703A1

The present disclosure relates generally to compositions and methods of treating cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising the administration of a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination therapy can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared to the administration of either the BET inhibitor or the chemotherapeutic agent alone.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver